1. Scrip
  3. >>Clinical Trials

Janssen/Legend’s Cilta-Cel Responses Could Make Up For Second-To-Market Position

Mitigation Strategy Lessens Neurotoxicity Of CAR-T In Myeloma

 
• By Mandy Jackson

Cilta-cel likely will be the second BCMA-targeting CAR-T therapy approved in the US for multiple myeloma, but appears to have an efficacy advantage over BMS/bluebird’s first-to-market Abecma.

Red number two inside a white circle and an arrow painted on concrete
The US FDA will decide whether to approve cilta-cel by 29 November • Source: Alamy

Already approved BCMA-targeting chimeric antigen receptor T-cell therapeutic Abecma (idecabtagene vicleucel) from Bristol Myers Squibb Company and bluebird bio has an eight-month head start over Janssen Pharmaceutical Cos. and Legend Biotech Corp.’s pending ciltacabtagene autoleucel (cilta-cel), but updated pivotal trial data for cilta-cel show response rates that could give the runner-up an advantage in the multiple myeloma market.

Janssen and Legend’s B-cell maturation antigen (BCMA)-targeting CAR-T therapy cilta-cel is under priority review at the US Food and Drug Administration with a 29 November action date. Abecma was approved in March for fifth-line or later relapsed or refractory multiple myeloma

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.